## Yu Wei

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/869726/publications.pdf

Version: 2024-02-01

27	542	12	22
papers	citations	h-index	g-index
27	27	27	723
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Inherited Mutations in Chinese Men With Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 54-62.	4.9	13
2	Re: Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.02.010. European Urology, 2022, , .	1.9	0
3	Stereotactic Radiotherapy for Lesions Detected via 68Ga-Prostate-specific Membrane Antigen and 18F-Fluorodexyglucose Positron Emission Tomography/Computed Tomography in Patients with Nonmetastatic Prostate Cancer with Early Prostate-specific Antigen Progression on Androgen Deprivation Therapy: A Prospective Single-center Study. European Urology Oncology. 2022. 5, 420-427.	5.4	12
4	Prevalence of comprehensive <scp>DNA</scp> damage repair gene germline mutations in Chinese prostate cancer patients. International Journal of Cancer, 2021, 148, 673-681.	5.1	20
5	Identification of a methylation panel aid in risk stratification in nodeâ€positive penile squamous cell carcinoma. International Journal of Cancer, 2021, 148, 1289-1298.	5.1	1
6	Epidemiology and genomics of prostate cancer in Asian men. Nature Reviews Urology, 2021, 18, 282-301.	3.8	111
7	The genomic landscape of Chinese patients with upper tract urothelial carcinoma Journal of Clinical Oncology, 2021, 39, e16583-e16583.	1.6	O
8	Genomic characteristics of homologous recombination deficiency in prostate cancer Journal of Clinical Oncology, 2021, 39, e17004-e17004.	1.6	0
9	Combination of body mass index and albumin predicts the survival in metastatic castrationâ€resistant prostate cancer patients treated with abiraterone: A post hoc analysis of two randomized trials. Cancer Medicine, 2021, 10, 6697-6704.	2.8	7
10	The U Shape of Prostate-specific Antigen and Prostate Cancer-specific Mortality in High-grade Metastatic Prostate Adenocarcinoma. European Urology Focus, 2020, 6, 53-62.	3.1	5
11	Comparison of different lymph node staging schemes in prostate cancer patients with lymph node metastasis. International Urology and Nephrology, 2020, 52, 87-95.	1.4	6
12	Importance of HPV in Chinese Penile Cancer: A Contemporary Multicenter Study. Frontiers in Oncology, 2020, 10, 1521.	2.8	9
13	Single-cell transcriptomics identifies a distinct luminal progenitor cell type in distal prostate invagination tips. Nature Genetics, 2020, 52, 908-918.	21.4	77
14	Prognostic Value of Local Treatment in Prostate Cancer Patients With Different Metastatic Sites: A Population Based Retrospective Study. Frontiers in Oncology, 2020, 10, 527952.	2.8	6
15	A Prospective Trial of 68Ga-PSMA and 18F-FDG PET/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration. Clinical Cancer Research, 2020, 26, 4551-4558.	7.0	49
16	Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer. Oncologist, 2020, 25, e1042-e1050.	3.7	17
17	Surgical Volume, Safety, Drug Administration, and Clinical Trials During COVID-19: Single-center Experience in Shanghai, China. European Urology, 2020, 78, 120-122.	1.9	11
18	GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers. Cancer Letters, 2020, 485, 45-55.	7.2	42

#	Article	IF	CITATION
19	Prognosis of the 8th TNM Staging System for Penile Cancer and Refinement of Prognostication by Incorporating High Risk Human Papillomavirus Status. Journal of Urology, 2020, 203, 562-569.	0.4	24
20	Germline mutations in DNA repair genes in a large series of unselected Chinese prostate cancer patients Journal of Clinical Oncology, 2020, 38, e17523-e17523.	1.6	0
21	A prospective trial of 68Ga-PSMA and 18F-FDG PET/CT in nonmetastatic prostate cancer patients with an early PSA progression during castration Journal of Clinical Oncology, 2020, 38, e17579-e17579.	1.6	31
22	Prognostic value of primary tumor surgery in seminoma patients with distant metastasis at diagnosis: a population-based study. Asian Journal of Andrology, 2020, 22, 602.	1.6	1
23	Elevated MRE11 expression associated with progression and poor outcome in prostate cancer. Journal of Cancer, 2019, 10, 4333-4340.	2.5	23
24	Lowâ€serum prostateâ€specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer. Prostate, 2019, 79, 1563-1571.	2.3	12
25	Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients. European Urology, 2019, 76, 280-283.	1.9	41
26	Germline DNA damage repair gene alterations in Chinese prostate patients: More than HRR and MMR Journal of Clinical Oncology, 2019, 37, e13041-e13041.	1.6	0
27	An Integrated Score and Nomogram Combining Clinical and Immunohistochemistry Factors to Predict High ISUP Grade Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2018, 8, 634.	2.8	24